Inhibikase Therapeutics, Inc. (IKT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Inhibikase Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Inhibikase Therapeutics, Inc. (IKT) has returned -18.05% so far this year and -23.29% over the past 12 months.

Based on dividend-adjusted daily data since Dec 23, 2020, IKT's average daily return is -0.09%, while the average monthly return is -1.98%.

Historically, 41% of months were positive and 59% were negative. The best month was Jan 2024 with a return of +137.4%, while the worst month was Jun 2021 at -47.7%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.

On a daily basis, IKT closed higher 44% of trading days. The best single day was Jan 24, 2024 with a return of +37.7%, while the worst single day was Nov 7, 2022 at -40.9%.

Inhibikase Therapeutics, Inc. has an annualized alpha of -28.46%, beta of 0.98, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since December 24, 2020.

• This stock participated in 143.67% of S&P 500 Index downside but only -88.40% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

IKT ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for Inhibikase Therapeutics, Inc. (IKT) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Inhibikase Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Inhibikase Therapeutics, Inc. was 98.64%, occurring on Oct 9, 2023. The portfolio has not yet recovered.

The current Inhibikase Therapeutics, Inc. drawdown is 97.17%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Inhibikase Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Inhibikase Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.